HomeMost PopularInvestingAbsci (ABSI) to Report Q1 Earnings: Here's What to Expect

Absci (ABSI) to Report Q1 Earnings: Here’s What to Expect

Actionable Trade Ideas

always free

Absci Corporation ABSI is scheduled to report first-quarter 2024 results on May 14.

Let’s see how things might have shaped up prior to the announcement.

Factors to Consider

Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients.

The company primarily generates revenues from drug-creation activities. ABSI is still early in the adoption phase of its drug creation model.

Hence, investors will mostly focus on pipeline updates.

In January, Absci presented positive preclinical data on ABS-101. Based on further confirmatory studies in February, Absci selected a development candidate to advance into IND-enabling studies. The company expects to submit an IND for ABS-101 in the first quarter of 2025 and commence phase I studies for this program thereafter, subject to IND clearance.

Another candidate, ABS-201, is designed for an undisclosed dermatological indication. The company expects to select a development candidate for this program in the second half of the year.

Meanwhile, ABS-301 is being evaluated for its broad applicability to a variety of oncology indications. Absci looks forward to completing the mode-of-action validation studies for this program in the second half as well.

Absci expects to advance at least one additional internal asset program to a lead stage in 2024.

Further updates on these candidates are expected when the company announces quarterly results.

As of Dec 31, 2023, the company had cash, cash equivalents and short-term investments worth $97.7 million.

Absci believes that its existing cash, cash equivalents and short-term investments, including the net proceeds from the recent underwritten offering of common stock (raising gross proceeds of approximately $86.4 million), should be sufficient to fund its operations into the first half of 2027.

Operating expenses increased in the fourth quarter of 2023. The first quarter, too, might have witnessed an increase in costs and expenses.

The Zacks Consensus Estimate for ABSI’s first-quarter revenues is pegged at $3 million, while the same for loss per share is pinned at 19 cents.

Earnings Surprise History

The company’s earnings missed estimates in each of the trailing four quarters, delivering an average negative surprise of 8.47%.

Absci Corporation Price, Consensus and EPS Surprise

Absci Corporation Price, Consensus and EPS Surprise

Absci Corporation price-consensus-eps-surprise-chart | Absci Corporation Quote

Earnings Whisper

Our proven model does not conclusively predict an earnings beat for ABSI this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Earnings ESP: ABSI has an Earnings ESP of 0.00% as the Most Accurate Estimate and the Zacks Consensus Estimate are both pegged at a loss of 19 cents.

Zacks Rank: ABSI currently carries a Zacks Rank #3.

Stocks to Consider

Here are some drug and biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this reporting cycle.

Adverum Biotechnologies ADVM has an Earnings ESP of +3.66% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

ADVM beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 3.58%. Shares of ADVM have surged 41.6% year to date.

ANI Pharmaceuticals ANIP has an Earnings ESP of +9.74% and a Zacks Rank #2 at present.

ANIP beat on earnings in each of the trailing four quarters, delivering an average surprise of 109.06%. It is scheduled to release first-quarter results on May 10.

Arvinas ARVN has an Earnings ESP of +20.71% and a Zacks Rank #2 at present.

ARVN beat on earnings in two of the trailing four quarters and missed in the other two, delivering an average negative surprise of 12.05%. Shares of ARVN have surged 30.7% in the past year.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

 

Where Will Stocks Go…

If Biden Wins? If Trump Wins?

The answers may surprise you.

Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!

Now is the time to download Zacks’ free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…

1. Medical manufacturer has gained +11,000% in the last 15 years.

2. Rental company is absolutely crushing its sector.

3. Energy powerhouse plans to grow its already large dividend by 25%.

4. Aerospace and defense standout just landed a potentially $80 billion contract.

5. Giant Chipmaker is building huge plants in the U.S. 

Hurry, Download Special Report FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report

Adverum Biotechnologies, Inc. (ADVM) : Free Stock Analysis Report

Arvinas, Inc. (ARVN) : Free Stock Analysis Report

Absci Corporation (ABSI) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.